Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Return on Invested Capital (2020 - 2024)

Insight Molecular Diagnostics' Return on Invested Capital history spans 3 years, with the latest figure at 2.56% for Q3 2024.

  • For Q3 2024, Return on Invested Capital changed N/A year-over-year to 2.56%; the TTM value through Sep 2024 reached 2.56%, changed N/A, while the annual FY2022 figure was 0.33%, 53.0% up from the prior year.
  • Return on Invested Capital for Q3 2024 was 2.56% at Insight Molecular Diagnostics, down from 2.1% in the prior quarter.
  • Across five years, Return on Invested Capital topped out at 0.3% in Q2 2021 and bottomed at 2.56% in Q3 2024.
  • The 3-year median for Return on Invested Capital is 0.69% (2020), against an average of 1.19%.
  • The largest YoY upside for Return on Invested Capital was 20bps in 2021 against a maximum downside of 20bps in 2021.
  • A 3-year view of Return on Invested Capital shows it stood at 0.79% in 2020, then grew by 26bps to 0.59% in 2021, then tumbled by -334bps to 2.56% in 2024.
  • Per Business Quant, the three most recent readings for IMDX's Return on Invested Capital are 2.56% (Q3 2024), 2.1% (Q2 2024), and 2.44% (Q1 2024).